U.S. markets closed

Advanced Proteome Therapeutics Corporation (APC.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.3550-0.0700 (-16.47%)
At close: 3:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4250
Open0.4250
Bid0.3450 x 0
Ask0.3600 x 0
Day's Range0.3450 - 0.4250
52 Week Range0.0800 - 0.5100
Volume112,929
Avg. Volume25,444
Market Cap13.259M
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0960
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO
      Newsfile

      Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO

      Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors

    • Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire
      Newsfile

      Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire

      Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.APTI is pleased to report that Dr. Ravi Chari is joining the Company's Scientific Advisory Board and Dr. Rajeshkumar Manian is joining as the lead organic chemist. Dr. ...

    • Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-Brokered Private Placement
      Newsfile

      Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-Brokered Private Placement

      Burnaby, British Columbia--(Newsfile Corp. - April 13, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the final tranche of its non-brokered private placement (the "Private Placement") raising gross proceeds of $524,610 by the issuance of 2,559,073 units at a price of $0.205 ...